[Immunocorrection in the combined treatment of patients with osteomyelitis developing following combined injuries to the maxillofacial and craniocerebral areas].
Twenty-one of the forty-two patients with osteomyelitis developing after a combined maxillofacial and craniocerebral injury were administered thymogen, an immunocorrective drug, as a component of combined therapy; immunologic indications for the prescription of such an agent were present in all these patients. Depressed T-cellular immunity was the principal disorder of the immunologic reactivity of this patient population; they also developed elevated counts of NK cells and increased interleukin synthesis by the macrophages, this reflecting a high activity of inflammation. Thymogen therapy was conducive to normalization of the immunologic and nonspecific reactivity and enhanced the treatment efficacy on the whole.